Manufacturing & innovation · 16 November 2026 · Stefan Bensmo

BAT’s nicotine pouch toxicant study: nine of eleven products were VELO

Short answer: A study in the peer-reviewed journal BMC Chemistry measured 132 analytes in eleven nicotine pouches and two snus products. According to the authors, the pouches contained more than 90 per cent lower levels than snus in most tests, and none exceeded the limits in the GOTHIATEK snus standard. But the study is not independent. Five of its six authors are BAT employees, and nine of the eleven pouches are BAT’s own VELO brand. The two competitor products are identified only as “CP1” and “CP2”. The study measures product content, not what users absorb and not health outcomes.

Editorial illustration of manufacturing and product innovation
Editorial illustration. It does not show real products.

Who is behind the study

ItemWhat the study states
PublicationBMC Chemistry 20, article 219, published 14 August 2026 (open access)
AuthorsSimone Hadley, Belinda Zonnestein, Jana Jeffery, Yen Nguyen and Helena Digard, all at BAT (Investments) Limited in Southampton, and Kevin McAdam, McAdam Scientific Ltd
ContactThe lead author, with a bat.com email address
Pouches testedNine VELO products from Nicoventures Trading Ltd (BAT) and two competitor products, CP1 (“Mini, Mint”, 8 mg) and CP2 (“Slim Spearmint”, 9 mg), with no brand names
ComparatorsThe 1S4 reference snus (University of Kentucky) and General Classic Blend White Portion Large (Swedish Match), bought in 2022. For cigarette smoke, published values for the 1R6F reference cigarette are used, with no new measurements
LaboratoriesIncluding Eurofins (US and Sweden) and Labstat (Canada)

The study does not explain why these two competitor products were chosen. The General snus brand is now owned by Philip Morris International through Swedish Match, BAT’s biggest rival in pouches. In other words, BAT chose both its own products and the products they are compared with.

We have not been able to read the journal’s funding and competing-interests declaration in full. With five of six authors employed by BAT, we assume BAT paid for the study, but we have not confirmed this.

What the study shows

According to the abstract, 70 of the 132 analytes could not be quantified in any of the products. 58 analytes were quantifiable in snus and 47 in the pouches. 15 were found only in snus and four only in one or more pouches. The authors write that the pouches contained more than 90 per cent lower levels than snus “in most tests”, and that no pouch exceeded GOTHIATEK, Swedish Match’s voluntary quality standard for snus.

The table also shows that the picture is not uniform. The values below are the lowest and highest per pouch among the products in which the analyte could be quantified.

AnalyteNicotine pouchesSnus
Tobacco-specific nitrosamines (NNN, NNK, NAT, NAB)Not detected in any pouchNNN 226–262 ng, NNK 75–79 ng
NickelQuantifiable in 5 of 11, highest 85.7 ng620–756 ng
LeadQuantifiable in 1 of 11, 26.9 ng99–127 ng
FormaldehydeQuantifiable in all 11, 0.33–2.69 µg1.01–1.17 µg
Ethyl carbamateQuantifiable in 3 of 11, highest 66.8 ngHighest 13.5 ng
AcroleinQuantifiable in 2 of 11, highest 0.28 µgNot quantifiable
NDBzA (nitrosamine)Quantifiable in 1 of 11, 3.3 ngNot detected
Nicotine5.4–20.3 mg5.9–7.2 mg

The highest formaldehyde level in a pouch was more than twice that in snus, and ethyl carbamate, acrolein and NDBzA were found in some pouches but not, or at lower levels, in snus. The study reports this, but it does not show in the “more than 90 per cent lower” headlines.

The authors’ conclusion is carefully worded: the results “support the hypothesis” that exclusive use of nicotine pouches “might offer a potentially reduced risk alternative” relative to continued smoking, and “comparable or even less risk” than snus.

What the study does not show

Why the study is surfacing now

The study was published in August 2026 but only spread in the trade press in mid-November, including through VapeBrief. That coincides with the delay of the European Commission’s proposal for a new Tobacco Products Directive (TPD3), and with nicotine pouch taxation returning to Ecofin in December. Manufacturers’ own measurement data become arguments in that debate. See TPD3 and nicotine pouches and VELO’s FDA authorization.

Our assessment

Frequently asked questions

Was the study done by BAT? Five of six authors are BAT employees, and nine of the eleven pouches tested are BAT’s VELO.

Does the study show nicotine pouches are harmless? No. It measures content, not health effects, and the authors themselves speak of a hypothesis.

Which competitor products were tested? It is not stated. They are called CP1 and CP2.

Method: This article is based on the study text in PubMed Central and at Springer Nature (BMC). Table values are taken from the study’s Table 3 (lowest and highest value per pouch). The funding and competing-interests declaration has not been reviewed in full. The article contains no health assessments of our own. Snapshot as of 16 November 2026.

Want to know how to disclose your products’ content in a way that holds up?

Book an initial call